{"transactions":[{"id":1276992,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2025-02-11T00:35:38.000Z","date":"2025-02-06","kind":"other","planned":false,"acquired":false,"shares":540000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See  footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on November 9, 2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 2,160,000 shares of Common Stock (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 2,160,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $339.1 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"While the Contracts were scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions the in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$10,433,585.66."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"kind","element":"transactionCoding","label":"F4","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on November 9, 2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 2,160,000 shares of Common Stock (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 2,160,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $339.1 million on or about the date of entering into the Contracts."},{"field":"kind","element":"transactionCoding","label":"F6","text":"While the Contracts were scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions the in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$10,433,585.66."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on November 9, 2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 2,160,000 shares of Common Stock (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 2,160,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $339.1 million on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"While the Contracts were scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions the in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$10,433,585.66."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on November 9, 2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 2,160,000 shares of Common Stock (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 2,160,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $339.1 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"While the Contracts were scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions the in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$10,433,585.66."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on November 9, 2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 2,160,000 shares of Common Stock (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 2,160,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $339.1 million on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"While the Contracts were scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions the in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$10,433,585.66."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on November 9, 2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 2,160,000 shares of Common Stock (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 2,160,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $339.1 million on or about the date of entering into the Contracts."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"While the Contracts were scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions the in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$10,433,585.66."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The Contracts were held by Counterparty and the Settlement Agreements were entered into by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Walgreens Schedule 13D, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":540000},"source":{"system":"sec-edgar","filing":"0000950170-25-017321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000095017025017321/ownership.xml","form_type":"4"}},{"id":1276991,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2025-02-11T00:35:38.000Z","date":"2025-02-06","kind":"other","planned":false,"acquired":false,"shares":540000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See  footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on November 9, 2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 2,160,000 shares of Common Stock (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 2,160,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $339.1 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"While the Contracts were scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions the in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$10,433,585.66."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"kind","element":"transactionCoding","label":"F4","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on November 9, 2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 2,160,000 shares of Common Stock (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 2,160,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $339.1 million on or about the date of entering into the Contracts."},{"field":"kind","element":"transactionCoding","label":"F6","text":"While the Contracts were scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions the in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$10,433,585.66."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on November 9, 2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 2,160,000 shares of Common Stock (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 2,160,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $339.1 million on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"While the Contracts were scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions the in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$10,433,585.66."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on November 9, 2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 2,160,000 shares of Common Stock (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 2,160,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $339.1 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"While the Contracts were scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions the in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$10,433,585.66."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on November 9, 2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 2,160,000 shares of Common Stock (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 2,160,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $339.1 million on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"While the Contracts were scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions the in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$10,433,585.66."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on November 9, 2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 2,160,000 shares of Common Stock (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 2,160,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $339.1 million on or about the date of entering into the Contracts."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"While the Contracts were scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions the in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$10,433,585.66."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The Contracts were held by Counterparty and the Settlement Agreements were entered into by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Walgreens Schedule 13D, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":540000},"source":{"system":"sec-edgar","filing":"0000950170-25-017321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000095017025017321/ownership.xml","form_type":"4"}},{"id":1276990,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2025-02-11T00:35:38.000Z","date":"2025-02-06","kind":"other","planned":false,"acquired":false,"shares":1080000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See  footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on November 9, 2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 2,160,000 shares of Common Stock (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 2,160,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $339.1 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"While the Contracts were scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions the in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$10,433,585.66."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"kind","element":"transactionCoding","label":"F4","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on November 9, 2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 2,160,000 shares of Common Stock (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 2,160,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $339.1 million on or about the date of entering into the Contracts."},{"field":"kind","element":"transactionCoding","label":"F6","text":"While the Contracts were scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions the in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$10,433,585.66."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on November 9, 2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 2,160,000 shares of Common Stock (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 2,160,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $339.1 million on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"While the Contracts were scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions the in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$10,433,585.66."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on November 9, 2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 2,160,000 shares of Common Stock (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 2,160,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $339.1 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"While the Contracts were scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions the in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$10,433,585.66."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on November 9, 2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 2,160,000 shares of Common Stock (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 2,160,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $339.1 million on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"While the Contracts were scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions the in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$10,433,585.66."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on November 9, 2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 2,160,000 shares of Common Stock (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 2,160,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $339.1 million on or about the date of entering into the Contracts."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"While the Contracts were scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions the in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$10,433,585.66."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The Contracts were held by Counterparty and the Settlement Agreements were entered into by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Walgreens Schedule 13D, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1080000},"source":{"system":"sec-edgar","filing":"0000950170-25-017321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000095017025017321/ownership.xml","form_type":"4"}},{"id":1276989,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2025-02-11T00:35:38.000Z","date":"2025-02-06","kind":"other","planned":false,"acquired":false,"shares":525000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See  footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"kind","element":"transactionCoding","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The Contracts were held by Counterparty and the Settlement Agreements were entered into by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Walgreens Schedule 13D, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":525000},"source":{"system":"sec-edgar","filing":"0000950170-25-017321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000095017025017321/ownership.xml","form_type":"4"}},{"id":1276988,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2025-02-11T00:35:38.000Z","date":"2025-02-06","kind":"other","planned":false,"acquired":false,"shares":525000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See  footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"kind","element":"transactionCoding","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The Contracts were held by Counterparty and the Settlement Agreements were entered into by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Walgreens Schedule 13D, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":525000},"source":{"system":"sec-edgar","filing":"0000950170-25-017321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000095017025017321/ownership.xml","form_type":"4"}},{"id":1276987,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2025-02-11T00:35:38.000Z","date":"2025-02-06","kind":"other","planned":false,"acquired":false,"shares":1575000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See  footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"kind","element":"transactionCoding","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The Contracts were held by Counterparty and the Settlement Agreements were entered into by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Walgreens Schedule 13D, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1575000},"source":{"system":"sec-edgar","filing":"0000950170-25-017321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000095017025017321/ownership.xml","form_type":"4"}},{"id":1276986,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2025-02-11T00:35:38.000Z","date":"2025-02-06","kind":"other","planned":false,"acquired":false,"shares":2625000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See  footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"kind","element":"transactionCoding","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The Contracts were held by Counterparty and the Settlement Agreements were entered into by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Walgreens Schedule 13D, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2625000},"source":{"system":"sec-edgar","filing":"0000950170-25-017321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000095017025017321/ownership.xml","form_type":"4"}},{"id":1276985,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-11T00:35:38.000Z","date":"2025-02-06","kind":"sale","planned":false,"acquired":false,"shares":204491,"price":244.51,"value":50000094.41,"ownership":{"direct":false,"nature":"See  footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Represents a sale in a private transaction to the Issuer by Walgreens Boots Alliance Holdings LLC."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The Contracts were held by Counterparty and the Settlement Agreements were entered into by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Walgreens Schedule 13D, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":12570000,"source":{"system":"sec-edgar","filing":"0000950170-25-017321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000095017025017321/ownership.xml","form_type":"4"}},{"id":1276984,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-11T00:35:38.000Z","date":"2025-02-06","kind":"other","planned":false,"acquired":false,"shares":447775,"price":244.51,"value":109485465.25,"ownership":{"direct":false,"nature":"See  footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"kind","element":"transactionCoding","label":"F4","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on November 9, 2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 2,160,000 shares of Common Stock (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 2,160,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $339.1 million on or about the date of entering into the Contracts."},{"field":"kind","element":"transactionCoding","label":"F6","text":"While the Contracts were scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions the in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$10,433,585.66."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The Contracts were held by Counterparty and the Settlement Agreements were entered into by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Walgreens Schedule 13D, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":12774491,"source":{"system":"sec-edgar","filing":"0000950170-25-017321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000095017025017321/ownership.xml","form_type":"4"}},{"id":1276983,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-11T00:35:38.000Z","date":"2025-02-06","kind":"other","planned":false,"acquired":false,"shares":439989,"price":244.51,"value":107581710.39,"ownership":{"direct":false,"nature":"See  footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"kind","element":"transactionCoding","label":"F4","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on November 9, 2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 2,160,000 shares of Common Stock (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 2,160,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $339.1 million on or about the date of entering into the Contracts."},{"field":"kind","element":"transactionCoding","label":"F6","text":"While the Contracts were scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions the in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$10,433,585.66."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The Contracts were held by Counterparty and the Settlement Agreements were entered into by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Walgreens Schedule 13D, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":13222266,"source":{"system":"sec-edgar","filing":"0000950170-25-017321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000095017025017321/ownership.xml","form_type":"4"}},{"id":1276982,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-11T00:35:38.000Z","date":"2025-02-06","kind":"other","planned":false,"acquired":false,"shares":879015,"price":244.51,"value":214927957.65,"ownership":{"direct":false,"nature":"See  footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"kind","element":"transactionCoding","label":"F4","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on November 9, 2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 2,160,000 shares of Common Stock (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 2,160,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $339.1 million on or about the date of entering into the Contracts."},{"field":"kind","element":"transactionCoding","label":"F6","text":"While the Contracts were scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions the in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$10,433,585.66."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The Contracts were held by Counterparty and the Settlement Agreements were entered into by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Walgreens Schedule 13D, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":13662255,"source":{"system":"sec-edgar","filing":"0000950170-25-017321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000095017025017321/ownership.xml","form_type":"4"}},{"id":1276981,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-11T00:35:38.000Z","date":"2025-02-06","kind":"other","planned":false,"acquired":false,"shares":437884,"price":244.51,"value":107067016.84,"ownership":{"direct":false,"nature":"See  footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"kind","element":"transactionCoding","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The Contracts were held by Counterparty and the Settlement Agreements were entered into by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Walgreens Schedule 13D, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":14541270,"source":{"system":"sec-edgar","filing":"0000950170-25-017321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000095017025017321/ownership.xml","form_type":"4"}},{"id":1276980,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-11T00:35:38.000Z","date":"2025-02-06","kind":"other","planned":false,"acquired":false,"shares":436653,"price":244.51,"value":106766025.03,"ownership":{"direct":false,"nature":"See  footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"kind","element":"transactionCoding","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The Contracts were held by Counterparty and the Settlement Agreements were entered into by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Walgreens Schedule 13D, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":14979154,"source":{"system":"sec-edgar","filing":"0000950170-25-017321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000095017025017321/ownership.xml","form_type":"4"}},{"id":1276979,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-11T00:35:38.000Z","date":"2025-02-06","kind":"other","planned":false,"acquired":false,"shares":1323172,"price":244.51,"value":323528785.72,"ownership":{"direct":false,"nature":"See  footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"kind","element":"transactionCoding","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The Contracts were held by Counterparty and the Settlement Agreements were entered into by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Walgreens Schedule 13D, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":15415807,"source":{"system":"sec-edgar","filing":"0000950170-25-017321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000095017025017321/ownership.xml","form_type":"4"}},{"id":1276978,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-11T00:35:38.000Z","date":"2025-02-06","kind":"other","planned":false,"acquired":false,"shares":2159136,"price":244.51,"value":527930343.36,"ownership":{"direct":false,"nature":"See  footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 6, 2025, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into early settlement agreements (the \"Settlement Agreements\") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the \"Contracts\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023.  As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts.  Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts.  In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts."},{"field":"kind","element":"transactionCoding","label":"F5","text":"While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The Contracts were held by Counterparty and the Settlement Agreements were entered into by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Walgreens Schedule 13D, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":16738979,"source":{"system":"sec-edgar","filing":"0000950170-25-017321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000095017025017321/ownership.xml","form_type":"4"}},{"id":1276977,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-11T00:35:38.000Z","date":"2025-02-06","kind":"sale","planned":false,"acquired":false,"shares":1081885,"price":244.51,"value":264531701.35,"ownership":{"direct":false,"nature":"See  footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a block sale pursuant to Rule 144 under the Securities Act of 1933, as amended, to an unaffiliated financial institution by Walgreens Boots Alliance Holdings LLC (the \"Block Sale\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the \"Walgreens Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The Contracts were held by Counterparty and the Settlement Agreements were entered into by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Walgreens Schedule 13D, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":18898115,"source":{"system":"sec-edgar","filing":"0000950170-25-017321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000095017025017321/ownership.xml","form_type":"4"}},{"id":1441131,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T22:44:32.000Z","date":"2024-08-01","kind":"sale","planned":false,"acquired":false,"shares":4438171,"price":240.56,"value":1067646415.76,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents a sale pursuant to Rule 144 (3,398,929 shares) and a sale in a private transaction to the Issuer (1,039,242 shares), in each case, by WBA Holdings."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024 and August 5, 2024 (the \"Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024 and August 5, 2024 (the \"Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares were held by Walgreens Boots Alliance Holdings LLC (\"WBA Holdings\"), an indirect wholly owned subsidiary of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"As described in the Schedule 13D, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of WBA Holdings, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":19980000,"source":{"system":"sec-edgar","filing":"0000950170-24-091058","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000095017024091058/ownership.xml","form_type":"4"}},{"id":1502319,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-05-24T20:05:18.000Z","date":"2024-05-22","kind":"sale","planned":false,"acquired":false,"shares":1859390,"price":215.1244,"value":400000158.116,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents a sale in a private transaction to the Issuer (1,859,390 shares) by WBA Holdings."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023 and February 9, 2024 (the \"Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023 and February 9, 2024 (the \"Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares were held by Walgreens Boots Alliance Holdings LLC (\"WBA Holdings\"), an indirect wholly owned subsidiary of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"As described in the Schedule 13D, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of WBA Holdings, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":24418171,"source":{"system":"sec-edgar","filing":"0000950170-24-064553","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000095017024064553/ownership.xml","form_type":"4"}},{"id":1651928,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-09T12:00:07.000Z","date":"2024-02-07","kind":"sale","planned":false,"acquired":false,"shares":4212395,"price":235.41,"value":991639906.95,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents sale pursuant to Rule 144 (4,000,0000 shares) and a sale in private transaction to the Issuer (212,395 shares), in each case, by WBA Holdings."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023 and February 9, 2024 (the \"Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023 and February 9, 2024 (the \"Schedule 13D\"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares were held by Walgreens Boots Alliance Holdings LLC (\"WBA Holdings\"), an indirect wholly owned subsidiary of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"As described in the Schedule 13D, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of WBA Holdings, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":26277561,"source":{"system":"sec-edgar","filing":"0000899243-24-000165","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924324000165/doc4.xml","form_type":"4"}},{"id":1742613,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-11-14T12:15:08.000Z","date":"2023-11-09","kind":"other","planned":false,"acquired":true,"shares":540000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On November 9, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,700,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $173.8838 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On November 9, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 9, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 9, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,700,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $173.8838 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 9, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,700,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $173.8838 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023 and November 14, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":540000,"derivative":{"underlying":"Common Stock","underlying_shares":540000},"source":{"system":"sec-edgar","filing":"0000899243-23-020341","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323020341/doc4.xml","form_type":"4"}},{"id":1742612,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-11-14T12:15:08.000Z","date":"2023-11-09","kind":"other","planned":false,"acquired":true,"shares":1080000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On November 9, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,700,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $173.8838 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On November 9, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 9, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 9, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,700,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $173.8838 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 9, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,700,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $173.8838 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023 and November 14, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":1080000,"derivative":{"underlying":"Common Stock","underlying_shares":1080000},"source":{"system":"sec-edgar","filing":"0000899243-23-020341","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323020341/doc4.xml","form_type":"4"}},{"id":1742611,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-11-14T12:15:08.000Z","date":"2023-11-09","kind":"other","planned":false,"acquired":true,"shares":540000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On November 9, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,700,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $173.8838 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On November 9, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 9, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 9, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,700,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $173.8838 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 9, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,700,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $173.8838 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023 and November 14, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":540000,"derivative":{"underlying":"Common Stock","underlying_shares":540000},"source":{"system":"sec-edgar","filing":"0000899243-23-020341","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323020341/doc4.xml","form_type":"4"}},{"id":1742610,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-11-14T12:15:08.000Z","date":"2023-11-09","kind":"other","planned":false,"acquired":true,"shares":540000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On November 9, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,700,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $173.8838 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On November 9, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 9, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 9, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,700,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $173.8838 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 9, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock (\"Common Stock\") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,700,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $173.8838 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023 and November 14, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":540000,"derivative":{"underlying":"Common Stock","underlying_shares":540000},"source":{"system":"sec-edgar","filing":"0000899243-23-020341","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323020341/doc4.xml","form_type":"4"}},{"id":1742609,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-14T12:15:08.000Z","date":"2023-11-09","kind":"sale","planned":false,"acquired":false,"shares":1279590,"price":195.375,"value":249999896.25,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale in a private transaction to the Issuer by WBA Holdings."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023 and November 14, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023 and November 14, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":30489956,"source":{"system":"sec-edgar","filing":"0000899243-23-020341","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323020341/doc4.xml","form_type":"4"}},{"id":1814030,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-08-07T21:48:51.000Z","date":"2023-08-03","kind":"other","planned":false,"acquired":true,"shares":2625000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023 and August 7, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":2625000,"derivative":{"underlying":"Common Stock","underlying_shares":2625000},"source":{"system":"sec-edgar","filing":"0000899243-23-017819","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323017819/doc4.xml","form_type":"4"}},{"id":1814029,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-08-07T21:48:51.000Z","date":"2023-08-03","kind":"other","planned":false,"acquired":true,"shares":1575000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023 and August 7, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":1575000,"derivative":{"underlying":"Common Stock","underlying_shares":1575000},"source":{"system":"sec-edgar","filing":"0000899243-23-017819","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323017819/doc4.xml","form_type":"4"}},{"id":1814028,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-08-07T21:48:51.000Z","date":"2023-08-03","kind":"other","planned":false,"acquired":true,"shares":525000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023 and August 7, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":525000,"derivative":{"underlying":"Common Stock","underlying_shares":525000},"source":{"system":"sec-edgar","filing":"0000899243-23-017819","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323017819/doc4.xml","form_type":"4"}},{"id":1814027,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-08-07T21:48:51.000Z","date":"2023-08-03","kind":"other","planned":false,"acquired":true,"shares":525000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023 and August 7, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":525000,"derivative":{"underlying":"Common Stock","underlying_shares":525000},"source":{"system":"sec-edgar","filing":"0000899243-23-017819","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323017819/doc4.xml","form_type":"4"}},{"id":1814026,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-08-07T21:48:51.000Z","date":"2023-08-03","kind":"other","planned":false,"acquired":true,"shares":1312500,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023 and August 7, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":1312500,"derivative":{"underlying":"Common Stock","underlying_shares":1312500},"source":{"system":"sec-edgar","filing":"0000899243-23-017819","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323017819/doc4.xml","form_type":"4"}},{"id":1814025,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-08-07T21:48:51.000Z","date":"2023-08-03","kind":"other","planned":false,"acquired":true,"shares":1050000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023 and August 7, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":1050000,"derivative":{"underlying":"Common Stock","underlying_shares":1050000},"source":{"system":"sec-edgar","filing":"0000899243-23-017819","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323017819/doc4.xml","form_type":"4"}},{"id":1814024,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-08-07T21:48:51.000Z","date":"2023-08-03","kind":"other","planned":false,"acquired":true,"shares":525000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023 and August 7, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":525000,"derivative":{"underlying":"Common Stock","underlying_shares":525000},"source":{"system":"sec-edgar","filing":"0000899243-23-017819","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323017819/doc4.xml","form_type":"4"}},{"id":1814023,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-08-07T21:48:51.000Z","date":"2023-08-03","kind":"other","planned":false,"acquired":true,"shares":525000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023 and August 7, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":525000,"derivative":{"underlying":"Common Stock","underlying_shares":525000},"source":{"system":"sec-edgar","filing":"0000899243-23-017819","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323017819/doc4.xml","form_type":"4"}},{"id":1814022,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-08-07T21:48:51.000Z","date":"2023-08-03","kind":"other","planned":false,"acquired":true,"shares":525000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023 and August 7, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":525000,"derivative":{"underlying":"Common Stock","underlying_shares":525000},"source":{"system":"sec-edgar","filing":"0000899243-23-017819","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323017819/doc4.xml","form_type":"4"}},{"id":1814021,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-08-07T21:48:51.000Z","date":"2023-08-03","kind":"other","planned":false,"acquired":true,"shares":525000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023 and August 7, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":525000,"derivative":{"underlying":"Common Stock","underlying_shares":525000},"source":{"system":"sec-edgar","filing":"0000899243-23-017819","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323017819/doc4.xml","form_type":"4"}},{"id":1814020,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-08-07T21:48:51.000Z","date":"2023-08-03","kind":"other","planned":false,"acquired":true,"shares":525000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023 and August 7, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":525000,"derivative":{"underlying":"Common Stock","underlying_shares":525000},"source":{"system":"sec-edgar","filing":"0000899243-23-017819","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323017819/doc4.xml","form_type":"4"}},{"id":1814019,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-08-07T21:48:51.000Z","date":"2023-08-03","kind":"other","planned":false,"acquired":true,"shares":262500,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 3, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with eight unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 10,500,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $1.6 billion on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 10,500,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $168.4512 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $217.6617 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from September 2, 2025 to October 13, 2025, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023 and August 7, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":262500,"derivative":{"underlying":"Common Stock","underlying_shares":262500},"source":{"system":"sec-edgar","filing":"0000899243-23-017819","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323017819/doc4.xml","form_type":"4"}},{"id":1814018,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-07T21:48:51.000Z","date":"2023-08-03","kind":"sale","planned":false,"acquired":false,"shares":1320858,"price":189.271,"value":250000114.518,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale in a private transaction to the Issuer by WBA Holdings."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023 and August 7, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023 and August 7, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":31769546,"source":{"system":"sec-edgar","filing":"0000899243-23-017819","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323017819/doc4.xml","form_type":"4"}},{"id":1850134,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-06-20T10:03:13.000Z","date":"2023-06-15","kind":"other","planned":false,"acquired":true,"shares":273750,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,190,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $161.2413 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $208.3455 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 15 valuation dates from March 3, 2025 to March 21, 2025, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,190,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $161.2413 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $208.3455 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 15 valuation dates from March 3, 2025 to March 21, 2025, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,190,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $161.2413 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $208.3455 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 15 valuation dates from March 3, 2025 to March 21, 2025, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023 and June 20, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":273750,"derivative":{"underlying":"Common Stock","underlying_shares":273750},"source":{"system":"sec-edgar","filing":"0000899243-23-015912","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323015912/doc4.xml","form_type":"4"}},{"id":1850133,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-06-20T10:03:13.000Z","date":"2023-06-15","kind":"other","planned":false,"acquired":true,"shares":273750,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,190,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $161.2413 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $208.3455 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 15 valuation dates from March 3, 2025 to March 21, 2025, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,190,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $161.2413 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $208.3455 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 15 valuation dates from March 3, 2025 to March 21, 2025, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,190,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $161.2413 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $208.3455 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 15 valuation dates from March 3, 2025 to March 21, 2025, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023 and June 20, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":273750,"derivative":{"underlying":"Common Stock","underlying_shares":273750},"source":{"system":"sec-edgar","filing":"0000899243-23-015912","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323015912/doc4.xml","form_type":"4"}},{"id":1850132,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-06-20T10:03:13.000Z","date":"2023-06-15","kind":"other","planned":false,"acquired":true,"shares":1095000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,190,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $161.2413 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $208.3455 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 15 valuation dates from March 3, 2025 to March 21, 2025, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,190,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $161.2413 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $208.3455 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 15 valuation dates from March 3, 2025 to March 21, 2025, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,190,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $161.2413 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $208.3455 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 15 valuation dates from March 3, 2025 to March 21, 2025, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023 and June 20, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":1095000,"derivative":{"underlying":"Common Stock","underlying_shares":1095000},"source":{"system":"sec-edgar","filing":"0000899243-23-015912","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323015912/doc4.xml","form_type":"4"}},{"id":1850131,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-06-20T10:03:13.000Z","date":"2023-06-15","kind":"other","planned":false,"acquired":true,"shares":273750,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,190,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $161.2413 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $208.3455 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 15 valuation dates from March 3, 2025 to March 21, 2025, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,190,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $161.2413 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $208.3455 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 15 valuation dates from March 3, 2025 to March 21, 2025, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,190,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $161.2413 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $208.3455 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 15 valuation dates from March 3, 2025 to March 21, 2025, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023 and June 20, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":273750,"derivative":{"underlying":"Common Stock","underlying_shares":273750},"source":{"system":"sec-edgar","filing":"0000899243-23-015912","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323015912/doc4.xml","form_type":"4"}},{"id":1850130,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-06-20T10:03:13.000Z","date":"2023-06-15","kind":"other","planned":false,"acquired":true,"shares":273750,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,190,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $161.2413 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $208.3455 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 15 valuation dates from March 3, 2025 to March 21, 2025, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,190,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $161.2413 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $208.3455 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 15 valuation dates from March 3, 2025 to March 21, 2025, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 15, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with five unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,190,000  shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $324.8 million on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 2,190,000  shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $161.2413 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $208.3455 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 15 valuation dates from March 3, 2025 to March 21, 2025, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023 and June 20, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":273750,"derivative":{"underlying":"Common Stock","underlying_shares":273750},"source":{"system":"sec-edgar","filing":"0000899243-23-015912","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323015912/doc4.xml","form_type":"4"}},{"id":1850129,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-20T10:03:13.000Z","date":"2023-06-15","kind":"sale","planned":false,"acquired":false,"shares":275984,"price":181.17,"value":50000021.28,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale in a private transaction to the Issuer by WBA Holdings."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023 and June 20, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023 and June 20, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":33090404,"source":{"system":"sec-edgar","filing":"0000899243-23-015912","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323015912/doc4.xml","form_type":"4"}},{"id":1893796,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-05-15T21:18:46.000Z","date":"2023-05-11","kind":"other","planned":false,"acquired":false,"shares":918000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On May 11, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 4,590,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $644.3 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 4,590,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $ $151.9853 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $ $196.3855 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stoc"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from June 2, 2025 to July 16, 2025, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On May 11, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 4,590,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $644.3 million on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 11, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 4,590,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $644.3 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On May 11, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 4,590,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $644.3 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 4,590,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $ $151.9853 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $ $196.3855 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stoc"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from June 2, 2025 to July 16, 2025, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On May 11, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 4,590,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $644.3 million on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 4,590,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $ $151.9853 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $ $196.3855 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stoc"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from June 2, 2025 to July 16, 2025, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022 and May 15, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":918000,"derivative":{"underlying":"Common Stock","underlying_shares":918000},"source":{"system":"sec-edgar","filing":"0000899243-23-012969","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323012969/doc4.xml","form_type":"4"}},{"id":1893795,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-05-15T21:18:46.000Z","date":"2023-05-11","kind":"other","planned":false,"acquired":false,"shares":918000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On May 11, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 4,590,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $644.3 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 4,590,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $ $151.9853 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $ $196.3855 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stoc"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from June 2, 2025 to July 16, 2025, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On May 11, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 4,590,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $644.3 million on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 11, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 4,590,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $644.3 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On May 11, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 4,590,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $644.3 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 4,590,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $ $151.9853 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $ $196.3855 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stoc"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from June 2, 2025 to July 16, 2025, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On May 11, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 4,590,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $644.3 million on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 4,590,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $ $151.9853 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $ $196.3855 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stoc"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from June 2, 2025 to July 16, 2025, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022 and May 15, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":918000,"derivative":{"underlying":"Common Stock","underlying_shares":918000},"source":{"system":"sec-edgar","filing":"0000899243-23-012969","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323012969/doc4.xml","form_type":"4"}},{"id":1893794,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-05-15T21:18:46.000Z","date":"2023-05-11","kind":"other","planned":false,"acquired":false,"shares":1836000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On May 11, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 4,590,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $644.3 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 4,590,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $ $151.9853 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $ $196.3855 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stoc"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from June 2, 2025 to July 16, 2025, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On May 11, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 4,590,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $644.3 million on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 11, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 4,590,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $644.3 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On May 11, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 4,590,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $644.3 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 4,590,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $ $151.9853 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $ $196.3855 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stoc"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from June 2, 2025 to July 16, 2025, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On May 11, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 4,590,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $644.3 million on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 4,590,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $ $151.9853 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $ $196.3855 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stoc"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from June 2, 2025 to July 16, 2025, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022 and May 15, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":1836000,"derivative":{"underlying":"Common Stock","underlying_shares":1836000},"source":{"system":"sec-edgar","filing":"0000899243-23-012969","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323012969/doc4.xml","form_type":"4"}},{"id":1893793,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Forward sale contract (obligation to sell)","published_at":"2023-05-15T21:18:46.000Z","date":"2023-05-11","kind":"other","planned":false,"acquired":false,"shares":918000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On May 11, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 4,590,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $644.3 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 4,590,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $ $151.9853 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $ $196.3855 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stoc"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from June 2, 2025 to July 16, 2025, inclusive."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On May 11, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 4,590,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $644.3 million on or about the date of entering into the Contracts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 11, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 4,590,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $644.3 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On May 11, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 4,590,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $644.3 million on or about the date of entering into the Contracts."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 4,590,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $ $151.9853 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $ $196.3855 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stoc"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from June 2, 2025 to July 16, 2025, inclusive."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On May 11, 2023, Walgreens Boots Alliance Holdings LLC (\"Counterparty\"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the \"Reporting Person\"), entered into variable pre-paid forward sale contracts (the \"Contracts\") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 4,590,000 shares of common stock (\"Common Stock\") of AmerisourceBergen Corporation (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $644.3 million on or about the date of entering into the Contracts."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[continued from FN (2)] Counterparty also pledged 4,590,000 shares of Common Stock (the \"Pledged Shares\") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"[continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the \"Reference Price\") is less than or equal to $ $151.9853 (the \"Floor Price\"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $ $196.3855 (the \"Cap Price\"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stoc"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"[continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Contracts are scheduled to mature evenly over a series of 30 valuation dates from June 2, 2025 to July 16, 2025, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022 and May 15, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":918000,"derivative":{"underlying":"Common Stock","underlying_shares":918000},"source":{"system":"sec-edgar","filing":"0000899243-23-012969","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323012969/doc4.xml","form_type":"4"}},{"id":1893792,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-15T21:18:46.000Z","date":"2023-05-11","kind":"sale","planned":false,"acquired":false,"shares":292792,"price":170.77,"value":50000089.84,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a sale in a private transaction to the Issuer by WBA Holdings."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022 and May 15, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022 and May 15, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These Contracts are held by Counterparty."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":33366388,"source":{"system":"sec-edgar","filing":"0000899243-23-012969","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924323012969/doc4.xml","form_type":"4"}},{"id":2090026,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-12T22:26:54.000Z","date":"2022-12-08","kind":"sale","acquired":false,"shares":5961534,"price":165.08,"value":984130032.72,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 4, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022 and November 9, 2022, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by Walgreens on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"security","element":"securityTitle","label":"F2","text":"These shares were held by Walgreens Boots Alliance Holdings LLC (\"WBA Holdings\"), an indirect wholly owned subsidiary of the Reporting Person."},{"field":"security","element":"securityTitle","label":"F3","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of WBA Holdings, may also be deemed to beneficially own the securities reported in this Form 4."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents sale pursuant to Rule 144 (4,750,000 shares) and a sale in private transaction to the Issuer (1,211,534 shares), in each case, by WBA Holdings."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 4, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022 and November 9, 2022, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by Walgreens on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 4, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022 and November 9, 2022, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by Walgreens on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares were held by Walgreens Boots Alliance Holdings LLC (\"WBA Holdings\"), an indirect wholly owned subsidiary of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of WBA Holdings, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":33659180,"source":{"system":"sec-edgar","filing":"0000899243-22-038256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924322038256/doc4.xml","form_type":"4"}},{"id":2121379,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-09T13:00:10.000Z","date":"2022-11-07","kind":"sale","acquired":false,"shares":13234153,"price":154.6,"value":2046000053.8,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 4, 2016, January 6, 2021, June 3, 2021, May 12, 2022 and August 4, 2022, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by Walgreens on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\") and include 2,000,000 shares acquired pursuant to the consummation of the transactions contemplated by the Share Purchase Agreement, dated as of January 6, 2021 (the \"SPA\"), by and between the Reporting Person and the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"These shares were held by Walgreens Boots Alliance Holdings LLC (\"WBA Holdings\"), an indirect wholly owned subsidiary of the Reporting Person."},{"field":"security","element":"securityTitle","label":"F3","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of WBA Holdings, may also be deemed to beneficially own the securities reported in this Form 4."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents sale in public offering to underwriters (10,000,000 shares) and a sale in private transaction to the Issuer (3,234,153 shares), in each case, by WBA Holdings."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 4, 2016, January 6, 2021, June 3, 2021, May 12, 2022 and August 4, 2022, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by Walgreens on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\") and include 2,000,000 shares acquired pursuant to the consummation of the transactions contemplated by the Share Purchase Agreement, dated as of January 6, 2021 (the \"SPA\"), by and between the Reporting Person and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 4, 2016, January 6, 2021, June 3, 2021, May 12, 2022 and August 4, 2022, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by Walgreens on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\") and include 2,000,000 shares acquired pursuant to the consummation of the transactions contemplated by the Share Purchase Agreement, dated as of January 6, 2021 (the \"SPA\"), by and between the Reporting Person and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares were held by Walgreens Boots Alliance Holdings LLC (\"WBA Holdings\"), an indirect wholly owned subsidiary of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of WBA Holdings, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":39629714,"source":{"system":"sec-edgar","filing":"0000899243-22-035407","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924322035407/doc4.xml","form_type":"4"}},{"id":2272351,"issuer":{"id":2994,"kind":"organization","name":"Cencora, Inc.","symbol":"COR"},"owners":[{"id":16467,"kind":"organization","name":"Walgreens Boots Alliance, Inc.","symbol":"WBA","position":1,"cik":"0001618921","reported_name":"Walgreens Boots Alliance, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83446,"kind":"organization","name":"Walgreens Boots Alliance Holdings LLC","position":2,"cik":"0001669077","reported_name":"Walgreens Boots Alliance Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-13T20:59:45.000Z","date":"2022-05-11","kind":"sale","acquired":false,"shares":6000000,"price":150,"value":900000000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 4, 2016, January 6, 2021, June 3, 2021 and May 12, 2022, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by Walgreens on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\") and include 2,000,000 shares acquired pursuant to the consummation of the transactions contemplated by the Share Purchase Agreement, dated as of January 6, 2021 (the \"SPA\"), by and between the Reporting Person and the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 4, 2016, January 6, 2021, June 3, 2021 and May 12, 2022, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by Walgreens on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\") and include 2,000,000 shares acquired pursuant to the consummation of the transactions contemplated by the Share Purchase Agreement, dated as of January 6, 2021 (the \"SPA\"), by and between the Reporting Person and the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares were held by Walgreens Boots Alliance Holdings LLC (\"WBA Holdings\"), an indirect wholly owned subsidiary of the Reporting Person."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of WBA Holdings, may also be deemed to beneficially own the securities reported in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As previously disclosed, including in the Schedule 13D filed by Walgreen Co. (\"Walgreens\") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 4, 2016, January 6, 2021, June 3, 2021 and May 12, 2022, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by Walgreens on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the \"Framework Agreement\") and include 2,000,000 shares acquired pursuant to the consummation of the transactions contemplated by the Share Purchase Agreement, dated as of January 6, 2021 (the \"SPA\"), by and between the Reporting Person and the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares were held by Walgreens Boots Alliance Holdings LLC (\"WBA Holdings\"), an indirect wholly owned subsidiary of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of WBA Holdings, may also be deemed to beneficially own the securities reported in this Form 4."}],"balance_after":52854867,"source":{"system":"sec-edgar","filing":"0000899243-22-018024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1140859/000089924322018024/doc4.xml","form_type":"4"}}]}